Platelet-Rich Plasma Injections for Osteoarthritis
Recruiting in Palo Alto (17 mi)
Overseen byMoin Khan, FRCSC
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 4
Recruiting
Sponsor: ArthroBiologix Inc.
Disqualifiers: Inflammatory osteoarthritis, Open wounds, others
No Placebo Group
Prior Safety Data
Approved in 3 Jurisdictions
Trial Summary
What is the purpose of this trial?The purpose of this study is to determine whether outcomes for patients receiving intra-articular platelet-rich plasma (PRP) injections for knee osteoarthritis are influenced by observation of the preparatory steps to the procedure. The viewing of the steps involved in the administration of PRP may increase the effectiveness of the treatment in comparison to patients who have not observed the preparatory steps.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Platelet-rich plasma (PRP) for osteoarthritis?
Research suggests that PRP injections may help reduce pain and promote cartilage repair in osteoarthritis, as PRP contains growth factors and anti-inflammatory signals that can improve joint health.
12345Is platelet-rich plasma (PRP) safe for humans?
Research on platelet-rich plasma (PRP) injections, including for osteoarthritis, suggests it is generally safe for humans, as it uses a person's own blood components, reducing the risk of adverse reactions.
34567How is platelet-rich plasma treatment different from other osteoarthritis treatments?
Platelet-rich plasma (PRP) treatment is unique because it uses a patient's own blood to create a concentrated mix of platelets that release growth factors and anti-inflammatory signals, potentially promoting joint repair and reducing inflammation, unlike most treatments that only address symptoms.
12345Eligibility Criteria
This trial is for men and women aged 50-80 with knee osteoarthritis, diagnosed through clinical exams and X-rays. Participants must be able to give informed consent. Details on who can't join are not provided.Inclusion Criteria
I am between 50 and 80 years old.
I have been diagnosed with knee osteoarthritis that causes symptoms.
Provision of informed consent
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
2-4 weeks
Treatment
Participants receive intra-articular platelet-rich plasma (PRP) injections for knee osteoarthritis, with or without observation of the preparatory steps
1 day
1 visit (in-person)
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessments of pain, function, and range of motion
12 weeks
Participant Groups
The study tests if watching the preparation of platelet-rich plasma (PRP) injections affects their effectiveness in treating knee osteoarthritis compared to those who don't watch the prep process.
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Viewing of preparationExperimental Treatment2 Interventions
The patient will be in the room for the preparation of the PRP and will receive a description of the centrifuge process from the physician administering the injection.
Group II: Blinded to preparationPlacebo Group1 Intervention
The patient will leave the room after their blood is drawn and will not view the preparation of the PRP, and will also not receive a description of the centrifuge process.
Platelet-rich plasma (PRP) is already approved in United States, Canada, European Union for the following indications:
🇺🇸 Approved in United States as Platelet-rich plasma for:
- Orthopedic conditions
- Wound care
- Dermatological conditions
- Hair restoration
🇨🇦 Approved in Canada as Platelet-rich plasma for:
- Orthopedic conditions
- Wound care
- Dermatological conditions
🇪🇺 Approved in European Union as Platelet-rich plasma for:
- Orthopedic conditions
- Wound care
- Dermatological conditions
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
ArthroBiologixHamilton, Canada
Loading ...
Who Is Running the Clinical Trial?
ArthroBiologix Inc.Lead Sponsor
References
Platelet-rich plasma injections induce disease-modifying effects in the treatment of osteoarthritis in animal models. [2021]The mechanisms of action and disease-modifying potential of platelet-rich plasma (PRP) injection for osteoarthritis (OA) treatment are still not fully established. The aim of this systematic review of preclinical evidence was to determine if PRP injections can induce disease-modifying effects in OA joints.
Effectiveness of Platelet-Rich Plasma in the Management of Knee Osteoarthritis in a Rural Clinic. [2022]Osteoarthritis (OA) is a degenerative disease causing decreased mobility. Use of autologous platelet-rich plasma (PRP) provides a reparative alternative in the management of OA.
Injection of platelet-rich plasma in patients with primary and secondary knee osteoarthritis: a pilot study. [2022]To evaluate the clinical effects of intraarticular platelet-rich plasma (PRP) injections in a small group of patients with primary and secondary osteoarthritis. Most of the current treatments for osteoarthritis are palliative and attack the symptoms rather than influencing the biochemical environment of the joint. Autologous platelet-rich plasma has emerged as a treatment option for tendinopathies and chronic wounds. In addition to release of growth factors, platelet-rich plasma also promotes concentrated anti-inflammatory signals including interleukin-1ra, which has been a focus of emerging treatments for osteoarthritis.
Editorial commentary: autologous platelet-rich plasma. [2018]Autologous platelet-rich plasma (PRP) is promising for osteoarthritis pain and may effect cartilage repair. Platelets are growth factor factories. Commercially available PRP is heterogeneous.
The influence of sample size and gender composition on the meta-analysis conclusion of platelet-rich plasma treatment for osteoarthritis. [2022]The magnitude of the therapeutic effects of intra-articular injection of platelet-rich plasma (PRP) on osteoarthritis (OA) is still under debate. The goal of this study that was a systematic review of randomised controlled trials of PRP injections for the treatment of OA was to elucidate the therapeutic efficacy of PRP.
Composition and Bioactivity of a Placental Tissue Particulate (PTP-001) Indicate Greater Potential than Platelet-Rich Plasma for the Treatment of Osteoarthritis. [2023]This study was conducted to compare therapeutically relevant properties of platelet-rich plasma (PRP), a commonly used autologous intra-articular treatment for osteoarthritis (OA), with those of a novel placental tissue particulate, PTP-001, which is in development as a regulated biologic treatment for knee OA.
Efficacy of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Meta-analysis of Randomized Controlled Trials. [2022]To use meta-analysis techniques to evaluate the efficacy and safety of platelet-rich plasma (PRP) injections for the treatment knee of osteoarthritis (OA).